Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Barclays Downgrades Siemens Energy as Valuation Seen Near Peak 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
RADNOR, Pa., May 06, 2018 -- Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Colony NorthStar, Inc. (NYSE:CLNS) (“Colony NorthStar” or the “Company”) on behalf of purchasers of the Company’s securities February 28, 2017 and March 1, 2018, inclusive (the “Class Period”).
Colony NorthStar investors are encouraged to visit www.kaskelalaw.com/case/colony-northstar to receive additional information about this action and submit their information online. Investors may also contact attorney D. Seamus Kaskela at (888) 715 – 1740, or via email at [email protected], to discuss their legal rights and options with respect to this action.
The shareholder class action complaint alleges that Colony NorthStar and certain of its senior executive officers made false and misleading statements and/or failed to disclose to investors that: (i) Colony NorthStar’s Healthcare and Investment Management segments were performing worse than reported; and (ii) as a result, Colony NorthStar’s public statements were materially false and misleading at all relevant times. The complaint further alleges that, as a result of the foregoing, investors purchased Colony NorthStar’s securities at artificially inflated prices during the Class Period and sustained significant investment losses when the truth was revealed.
On March 1, 2018, Colony NorthStar reported its financial and operating results for the quarter and year ended December 31, 2017. Therein the Company disclosed to investors a goodwill impairment of $375 million attributable to its Healthcare and Investment Management segments.
Following this news, shares of the Company’s stock fell $1.78 per share, or nearly 23%, to close on March 1, 2018 at $6.00 per share.
Investors who purchased Colony NorthStar securities during the Class Period may, no later than June 5, 2018, seek to be appointed as a lead plaintiff representative of the class through Kaskela Law or other counsel, or may choose to do nothing and remain an absent class member. In order to be appointed as a lead plaintiff a class member must meet certain legal requirements.
Kaskela Law LLC exclusively prosecutes shareholder actions in state and federal courts throughout the country on behalf of investors. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.
Investors who wish to discuss this action, their legal rights, or submit their information to Kaskela Law LLC for review are encouraged to contact the Firm or complete the information form on this page.
CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
201 King of Prussia Road
Suite 650
Radnor, PA 19087
(888) 715 – 1740
[email protected]
www.kaskelalaw.com
